Molecular Detection Inks Distribution Deal with Eldan for Israel, Palestinian Territories | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular Detection and Eldan today announced an exclusive agreement for distribution of MDI's Detect-Ready MRSA panel in Israel and the Palestinian territories.

Financial and other terms of the deal were not disclosed. Eldan, based in Petach Tikva, Israel, is a diagnostic distributor that is part of the Neopharm Group.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.